222 related articles for article (PubMed ID: 22750941)
1. [Kidney and bone update : the 5-year history and future of CKD-MBD. Parathyroidectomy for secondary hyperparathyroidism].
Tominaga Y
Clin Calcium; 2012 Jul; 22(7):1083-8. PubMed ID: 22750941
[TBL] [Abstract][Full Text] [Related]
2. [Chronic kidney disease (CKD) and bone. The clinical perspective of parathyroid interventional therapy for advanced secondary hyperparathyroidism in the era of cinacalcet HCl].
Tominaga Y
Clin Calcium; 2009 Apr; 19(4):545-50. PubMed ID: 19329834
[TBL] [Abstract][Full Text] [Related]
3. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.
Tominaga Y; Matsuoka S; Uno N; Sato T
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S21-6. PubMed ID: 19032523
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.
Zitt E; Rix M; Ureña Torres P; Fouque D; Jacobson SH; Pétavy F; Dehmel B; Ryba M
Nephrol Dial Transplant; 2011 Jun; 26(6):1956-61. PubMed ID: 20947534
[TBL] [Abstract][Full Text] [Related]
5. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
Uemura K; Kakuta T
Clin Calcium; 2010 Jul; 20(7):1104-10. PubMed ID: 20585190
[TBL] [Abstract][Full Text] [Related]
6. Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial.
Wang AY; Lo WK; Cheung SC; Tang TK; Yau YY; Lang BH
Nephrol Dial Transplant; 2023 Jul; 38(8):1823-1835. PubMed ID: 36869794
[TBL] [Abstract][Full Text] [Related]
7. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.
Komaba H; Moriwaki K; Goto S; Yamada S; Taniguchi M; Kakuta T; Kamae I; Fukagawa M
Am J Kidney Dis; 2012 Aug; 60(2):262-71. PubMed ID: 22445709
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of parathyroidectomy versus cinacalcet in the clinical management of secondary hyperparathyroidism.
Kim WW; Rhee Y; Kim BS; Kim K; Lee CR; Kang SW; Lee J; Jeong JJ; Nam KH; Chung WY
Endocr J; 2019 Oct; 66(10):881-889. PubMed ID: 31189770
[TBL] [Abstract][Full Text] [Related]
13. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
14. Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis.
Chen L; Wang K; Yu S; Lai L; Zhang X; Yuan J; Duan W
Ren Fail; 2016 Aug; 38(7):1050-8. PubMed ID: 27198474
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Parathyroidectomy for Secondary and Tertiary Hyperparathyroidism by the Parathyroid Surgeons' Society of Japan.
Tominaga Y; Kakuta T; Yasunaga C; Nakamura M; Kadokura Y; Tahara H
Ther Apher Dial; 2016 Feb; 20(1):6-11. PubMed ID: 26879490
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
Iseki K
Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
[TBL] [Abstract][Full Text] [Related]
17. Tertiary hyperparathyroidism resistant to cinacalcet treatment.
Okada M; Tominaga Y; Izumi K; Nobata H; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Nanmoku K; Watarai T; Uchida K
Ther Apher Dial; 2011 Jun; 15 Suppl 1():33-7. PubMed ID: 21595850
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
Quarles LD
Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
[TBL] [Abstract][Full Text] [Related]
19. Calcimimetics versus parathyroidectomy: What is preferable?
Rroji M; Spasovski G
Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
